Edition:
United Kingdom

Imprimis Pharmaceuticals Inc (IMMY.OQ)

IMMY.OQ on NASDAQ Stock Exchange Capital Market

1.72USD
2:35pm GMT
Change (% chg)

$0.03 (+1.78%)
Prev Close
$1.69
Open
$1.72
Day's High
$1.72
Day's Low
$1.72
Volume
6,726
Avg. Vol
129,633
52-wk High
$4.68
52-wk Low
$1.35

Select another date:

Tue, Jan 30 2018

BRIEF-Imprimis Pharma Makes Available Two Glaucoma Drugs On FDA's Drug Shortage List

* IMPRIMIS PHARMACEUTICALS NOW MAKING AVAILABLE TWO GLAUCOMA DRUGS ON FDA'S DRUG SHORTAGE LIST Source text for Eikon: Further company coverage:

BRIEF-Imprimis Pharmaceuticals Is Issued DEA Manufacturer Certificate For Its 503B Outsourcing Facility

* IMPRIMIS PHARMACEUTICALS IS ISSUED DEA MANUFACTURER CERTIFICATE FOR ITS 503B OUTSOURCING FACILITY Source text for Eikon: Further company coverage:

Imprimis receives FDA warning over eye medication advertising

Jan 16 The U.S. Food and Drug Administration has issued a warning letter to Imprimis Pharmaceuticals Inc accusing it of making false or misleading claims that its compounded eye medications had the agency's approval.

BRIEF-Imprimis Pharmaceuticals Q3 loss per share $‍0.28​

* Imprimis Pharmaceuticals announces third quarter 2017 results

Imprimis Pharma to take on Allergan's Restasis with cheaper product

Shares of Imprimis Pharmaceuticals Inc sky-rocketed as much as 91 percent on Thursday, after the company said it would launch a cheaper alternative to Allergan Plc's controversial dry eye drug, Restasis, by next month.

UPDATE 3-Imprimis Pharma to take on Allergan's Restasis with cheaper product

Oct 19 Shares of Imprimis Pharmaceuticals Inc sky-rocketed as much as 91 percent on Thursday, after the company said it would launch a cheaper alternative to Allergan Plc's controversial dry eye drug, Restasis, by next month.

BRIEF-Imprimis Pharma CEO says company intends to start selling prescriptions for its cheaper alternative to Restasis on Nov 1‍​

* CEO - Intends to start selling prescriptions for its cheaper alternative to Restasis on November 1‍​ Further company coverage:

Imprimis Pharma to take on Allergan's Restasis with cheaper product

Oct 19 Shares of Imprimis Pharmaceuticals sky-rocketed as much as 91.1 percent on Thursday, after it said it would offer a cheaper option to Allergan's dry eye disease medicine, Restasis.

BRIEF-Imprimis Pharmaceuticals to offer compounded Cyclosporine alternative to Restasis

* Imprimis Pharmaceuticals-‍making compounded Cyclosporine-based formulations available for physicians to consider prescribing as alternatives to Restasis​ Source text for Eikon: Further company coverage:

BRIEF-FDA Curcumin Investigation supports Imprimis statement

* Imprimis Pharmaceuticals Inc - ‍provided an update regarding FDA Medwatch notice issued on August 4, 2017​

Select another date: